WuXi Biologics (Cayman) Analysis (April) 2026

WuXi Biologics (Caym...

SEHK:2269

HK$ 34,98

HK$0,00 (0,00%)

34,98 HK$

HK$0,00 (0,00%)

End-of-day quote: 04/03/2026

WuXi Biologics (Cayman) Stock Value

According to analysts, the current valuation of SEHK:2269 is Outperform.

Outperform

WuXi Biologics (Cayman) Company Info

EPS Growth 5Y

29,27%

Market Cap

HK$144,73 B

Long-Term Debt

HK$0,19 B

Quarterly earnings

08/19/2026 (E)

Dividend

HK$0,00

Dividend Yield

0,00%

Founded

2014

Industry

Health Care

Country

China

Website

WuXi Biologics (Cayman)

ISIN Number

KYG970081173

Website

http://www.wuxibiologics.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$45,20

29.22%

Last Update: 04/03/2026

Analysts: 23

Highest Price Target HK$54,66

Average Price Target HK$45,20

Lowest Price Target HK$31,37

In the last five quarters, WuXi Biologics (Cayman)’s Price Target has risen from HK$31,33 to HK$69,40 - a 121,51% increase. Fourteen analysts predict that WuXi Biologics (Cayman)’s share price will increase in the coming year, reaching HK$45,20. This would represent an increase of 29,22%.

Top growth stocks in the health care sector (5Y.)

What does WuXi Biologics (Cayman) do?

WuXi Biologics (Cayman) Inc. an investment holding company that provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry. Business Segments The company operates through two primary segments, Biologics and XDC. Biologics The Biologics segment focuses on the discovery, development, and manufacturing of biologics, providing essential services that ensure the successful production of biologics for clinical trials and commercial use...

WuXi Biologics (Cayman) Inc. an investment holding company that provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry.

Business Segments

The company operates through two primary segments, Biologics and XDC.

Biologics

The Biologics segment focuses on the discovery, development, and manufacturing of biologics, providing essential services that ensure the successful production of biologics for clinical trials and commercial use. This segment encompasses a variety of capabilities, including cell line development, process development, and comprehensive analytical services designed to meet the rigorous standards set forth in the biotechnology field. The company leverages its extensive expertise and advanced technology platforms to foster innovation and ensure that biopharmaceutical clients can efficiently bring their products to market.

XDC

The XDC segment specializes in drug substance and product development, focusing on providing bioreactor capacity solutions, along with integrated development and manufacturing services intended directly at the needs of clients who seek to develop and produce therapeutic proteins.

Business Strategy

The strategy of the company is centered on being a global leader in the biologics industry through the provision of high-quality, comprehensive services that enhance drug discovery and development. The company's business strategy involves a strong commitment to technological innovation, operational excellence, and market responsiveness, enabling it to meet the increasing demands of the biopharmaceutical sector.

A key facet of the business strategy is the continuous enhancement of its service offerings. The company diligently invests in research and development to pioneer new technologies and improve existing processes. By fostering a culture of innovation, the company significantly enhances its competitive edge and provides state-of-the-art services to its clients. The commitment to incorporating industry best practices and maintaining stringent quality assurance policies ensures that the company consistently meets and exceeds client expectations.

The company emphasizes strategic partnerships and collaborations with industry stakeholders, academic institutions, and research organizations. These alliances allow the company to broaden its scientific expertise, enhance its technical capabilities, and extend its reach in the global market. Additionally, the company maintains a strong focus on geographical expansion seeking to penetrate new markets while reinforcing its presence in existing ones.

Products and Services

The company provides a broad spectrum of products and services tailored to meet the diverse needs of clients in the biologics sector. The company's service portfolio is categorized primarily into biologics development services and manufacturing services.

In biologics development, the company offers integrated services that span the entire drug development process. This includes cell line development, which is fundamental for the generation of high-yield production cell lines, and comprehensive process development, where methodologies are optimized for maximum efficiency. The company's analytical services encompass a wide range of testing protocols that comply with regulatory standards, ensuring the safety and efficacy of therapeutic products.

Manufacturing services provided by the company focus on both drug substance and drug product. The company boasts state-of-the-art facilities equipped with advanced bioreactor technology, capable of supporting large-scale production, thereby enabling swift movement from clinical trials to commercial manufacturing. The commitment to maintaining compliance with global regulatory requirements is paramount in all manufacturing processes, ensuring that products meet the expectations of international markets.

Additionally, the company continually invests in the improvement of its manufacturing capabilities. This includes scaling operations and enhancing efficiencies to better serve the needs of clients. The integration of digital technologies further strengthens its manufacturing processes, streamlining workflows and improving overall productivity.

Geographical Markets

The company caters to a global client base, with substantial revenue generated from North America, Europe, the People's Republic of China (PRC), and other regions worldwide.

Recent Acquisitions

The company has recently strengthened its market position through strategic acquisitions and partnerships. The establishment of WuXi XDC as a separate subsidiary listed on the Main Board of the Stock Exchange. This segment specializes in drug substance and product development, further elevating the company’s comprehensive service offerings within the industry.

Customers

The company serves a diverse array of clients across the global biopharmaceutical industry. The customer base includes emerging biotech firms, established pharmaceutical companies, and research organizations seeking comprehensive biologics solutions. The company’s client category encompasses organizations at various stages of the drug development lifecycle, from early-stage discovery to late-phase clinical trials.

Marketing

The company employs a multifaceted marketing strategy for promoting its comprehensive service offerings in the biologic’s domain. The company utilizes direct sales teams, digital marketing initiatives, and participation in key industry conferences to enhance visibility and engagement with potential clients. Sales professionals leverage their extensive industry knowledge and relationships to understand customer needs and articulate the value proposition of the company’s services. Distribution channels for the company’s services are primarily direct, with the company maintaining close collaborations with clients to ensure seamless project execution.

Government Regulations

The company adheres to standards set by various regulatory bodies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency, and other pertinent organizations governing drug development and manufacturing.

History

WuXi Biologics (Cayman) Inc. was founded in 2014. The company was incorporated in 2014.

WuXi Biologics (Cayman) Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue by Segment:** - **Biopharmaceutical Services:** 70% - **Research and Development (R&D):** 20% - **Manufacturing and Production:** 10% **TOP 3 Markets and their Percentage Shares:** - **USA:** 45% - **China:** 30% - **Europe:** 15% WuXi Biologics generates the majority of its revenue...

At which locations are the company’s products manufactured?

**Production sites of WuXi Biologics:** - **China:** Multiple sites, including Wuxi, Shanghai, and Suzhou. - **Ireland:** Dundalk. - **Germany:** Leverkusen. - **USA:** Massachusetts. In recent years, WuXi Biologics has significantly expanded its production capacities. In China, the company operate...

What strategy does WuXi Biologics (Cayman) pursue for future growth?

**Revenue Growth:** 20% (2024) **Investment in R&D:** 30% of revenue (2024) WuXi Biologics pursues a strategy of sustainable growth through significant investments in research and development. The company plans to further expand its capacities in the field of biologics production to meet the in...

Which raw materials are imported and from which countries?

**Main raw materials:** Biological raw materials, chemicals, laboratory equipment **Countries of origin:** USA, Germany, China WuXi Biologics imports a variety of raw materials and materials necessary for biopharmaceutical production. These include biological raw materials such as cell lines and p...

How strong is the company’s competitive advantage?

**Market share:** 10% (estimated, 2025) **R&D investments:** 20% of revenue (2024) **Customer retention:** 85% (2024) WuXi Biologics (Cayman) Inc. has a significant competitive advantage in the biopharmaceutical industry, especially through its comprehensive services in biologics developmen...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approx. 70% (2025, estimated based on historical data) **Insider Buys/Sells:** No significant transactions in the last year (2025, estimated) The institutional investor share at WuXi Biologics is traditionally high, as the company is considered a leading provider...

What percentage market share does WuXi Biologics (Cayman) have?

**Market Share of WuXi Biologics:** Estimated 12% (2025) **Top Competitors and Their Market Shares:** 1. **Lonza Group AG:** 15% 2. **Samsung Biologics:** 14% 3. **WuXi Biologics (Cayman) Inc.:** 12% 4. **Catalent, Inc.:** 10% 5. **Boehringer Ingelheim BioXcellence:** 8% 6. **Thermo Fisher Scientif...

Is WuXi Biologics (Cayman) stock currently a good investment?

**Revenue Growth:** 18% (2024) **R&D Investments:** 12% of revenue (2024) **Market Share in CDMO Sector:** 10% (2024) In 2024, WuXi Biologics achieved a revenue growth of 18%, driven by increasing demand for its contract development and manufacturing services (CDMO). The company continues to he...

Does WuXi Biologics (Cayman) pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (as of 2025) WuXi Biologics (Cayman) Inc. has not distributed any dividends to its shareholders so far. The company typically reinvests its profits in the growth and expansion of its business model, especially in research and development, as well as in expanding it...

New support ticket

Explore

WuXi Biologics (Cayman) Stock Value

WuXi Biologics (Cayman) Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does WuXi Biologics (Cayman) do?

WuXi Biologics (Cayman) Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

WuXi Biologics (Cayman) Stock Value

WuXi Biologics (Cayman) Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does WuXi Biologics (Cayman) do?

WuXi Biologics (Cayman) Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.